Imaging Brain Metabolism Using MRS of Hyperpolarized 13C-Pyruvate

使用超极化 13C-丙酮酸 MRS 成像脑代谢

基本信息

  • 批准号:
    9269573
  • 负责人:
  • 金额:
    $ 50.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-15 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Magnetic resonance spectroscopy (MRS) of hyperpolarized 13C-labeled substrates provides unique noninvasive measurements of critical dynamic metabolic processes, with hyperpolarized [1-13C]pyruvate (Pyr) being the first (and currently only) 13C-compound to reach the clinic. Occupying a key nodal point in energy metabolism, among the fates of Pyr are reduction to lactate (Lac) as the end product of glycolysis (GLY), amidation to produce alanine (Ala), or conversion in mitochondria to form acetyl CoA and CO2 (measured with 13C-MRS as a 13C-bicarbonate [Bic] peak) as the first step towards oxidative phosphorylation (OXPHOS) via the tricarboxylic acid (TCA) cycle. To date, the most prominent applications of hyperpolarized 13C-Pyr metabolic imaging are studies of cancer and heart disease. With a growing interest into cancer metabolic reprogramming fueling new studies into Warburg's 1965 observation that less energy-efficient aerobic GLY is favored in neoplasms over more efficient OXPHOS, MRS of hyperpolarized 13C-Pyr and the subsequent labeling of 13C-Lac provides an unprecedented noninvasive measurement of GLY. While 13C-Lac changes have now been well documented in multiple brain tumors and other neoplasms, these cancer studies have been largely silent on other downstream Pyr metabolic products, which can provide important information beyond glycolytic capacity. A more complete understanding of cancer metabolism requires measurements reflecting the complex interplay between both GLY and OXPHOS, and our preliminary findings with a glioblastoma multiforme model demonstrate that imaging Pyr products beyond Lac can provide this information. Energy regulation and mitochondrial function are also critically important for understanding brain function, and current data suggest a complex relationship involving the exchange of metabolic intermediates between glia and neurons. Conventional 13C MRS is well established as the primary noninvasive tool to study neuroenergetics and linked neurotransmitter cycling, but hyperpolarized 13C-MRS, with its high spatial and temporal resolution, has the potential to provide new insights. Although hyperpolarized [1-13C]Pyr provides little information on the TCA cycle, in vivo measurements downstream metabolic products of [2-13C]Pyr, for which the 13C-label is retained with the conversion of Pyr to acetyl-CoA, potentially add significant insights ino both OXPHOS and mitochondrial function. However, outside of the heart, few results concerning [2-13C]Pyr products beyond Lac (and Ala) have been reported. We believe the dearth of brain research on downstream Pyr products beyond Lac is due to the low signal- to-noise ratio (SNR) and other imaging difficulties associated with these resonances, rather than a lack of biochemical significance. The overall goal of this 4-year technical development grant is to develop optimized methods for imaging brain energy metabolism using hyperpolarized 13C-pyruvate in order to assess GLY, OXPHOS, and mitochondrial function. Many of to-be-developed methods will also be applicable to other organs and diseases. The Specific Aims are to develop improved acquisition and quantification methods for use with [1-13C]Pyr (Aim 1) and [2-13C]Pyr (Aim 2), assess Pyr metabolism and anti-VEGF treatment response in a rat C6-glioma model (Aim 3), and optimize sequences and hardware for future clinical hyperpolarized 13C- Pyr studies (Aim 4).
 描述(由申请人提供):超极化13 C标记底物的磁共振波谱(MRS)提供了关键动态代谢过程的独特非侵入性测量,超极化[1- 13 C]丙酮酸盐(Pyr)是第一个(目前唯一)到达临床的13 C化合物。在能量代谢中占据关键节点,Pyr的命运包括还原为乳酸(Lac)作为糖酵解(GLY)的最终产物,酰胺化产生丙氨酸(Ala),或在线粒体中转化形成乙酰CoA和CO2(用13 C-MRS测量为13 C-碳酸氢盐[Bic]峰)作为通过三羧酸(TCA)循环进行氧化磷酸化(OXPHOS)的第一步。迄今为止,超极化13 C-Pyr代谢成像最突出的应用是癌症和心脏病的研究。随着对癌症代谢重编程的兴趣日益增长,推动了对瓦尔堡1965年的观察的新研究,即能量效率较低的有氧GLY在肿瘤中比更有效的OXPHOS更受欢迎,超极化13 C-Pyr的MRS和随后的13 C-Lac标记提供了GLY的前所未有的非侵入性测量。虽然13 C-Lac的变化现在已经在多种脑肿瘤和其他肿瘤中得到了很好的记录,但这些癌症研究在很大程度上对其他下游Pyr代谢产物保持沉默,这些产物可以提供糖酵解能力之外的重要信息。更全面地了解癌症代谢需要反映GLY和OXPHOS之间复杂相互作用的测量,我们对多形性胶质母细胞瘤模型的初步研究结果表明,Lac以外的Pyr产品成像可以提供这些信息。能量调节和线粒体功能对于理解脑功能也至关重要,目前的数据表明,神经胶质细胞和神经元之间的代谢中间产物交换存在复杂的关系。传统的13 C MRS是研究神经能量学和相关神经递质循环的主要非侵入性工具,但超极化13 C-MRS具有高空间和时间分辨率,有可能提供新的见解。尽管超极化[1- 13 C]Pyr提供了关于TCA循环的很少信息,但[2- 13 C]Pyr下游代谢产物的体内测量(其中13 C-标记随着Pyr转化为乙酰辅酶A而保留)潜在地增加了对OXPHOS和线粒体功能的显著了解。然而,在心脏之外,关于Lac(和Ala)以外的[2- 13 C]Pyr产物的结果很少报道。我们认为,缺乏对Lac以外的下游Pyr产物的大脑研究是由于低信噪比(SNR)和与这些共振相关的其他成像困难,而不是缺乏生化意义。这项为期4年的技术开发资助的总体目标是开发使用超极化13 C-丙酮酸盐成像脑能量代谢的优化方法,以评估GLY,OXPHOS和线粒体功能。许多有待开发的方法也将适用于其他器官和疾病。具体目的是开发用于[1- 13 C]Pyr(目的1)和[2- 13 C]Pyr(目的2)的改进的采集和定量方法,评估大鼠C6-胶质瘤模型中的Pyr代谢和抗VEGF治疗反应(目的3),并优化未来临床超极化13 C- Pyr研究的序列和硬件(目的4)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel M Spielman其他文献

Daniel M Spielman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel M Spielman', 18)}}的其他基金

Enhanced Deuterium Metabolic Imaging (DMI) of Metabolic Reprogramming in Brain Tumors
脑肿瘤代谢重编程的增强氘代谢成像 (DMI)
  • 批准号:
    10593853
  • 财政年份:
    2023
  • 资助金额:
    $ 50.4万
  • 项目类别:
Robust 1H MRSI of GABA, Glutamate, Glutamine, and Glutathione
GABA、谷氨酸、谷氨酰胺和谷胱甘肽的稳定 1H MRSI
  • 批准号:
    9910230
  • 财政年份:
    2017
  • 资助金额:
    $ 50.4万
  • 项目类别:
Novel MRS methods for measuring brain energetics and neurotransmitter cycling
用于测量大脑能量学和神经递质循环的新 MRS 方法
  • 批准号:
    8990476
  • 财政年份:
    2015
  • 资助金额:
    $ 50.4万
  • 项目类别:
Hyperpolarizer for 13C MR Metabolic Imaging of Human Subjects and Animal Models
用于人类受试者和动物模型 13C MR 代谢成像的超极化器
  • 批准号:
    8333704
  • 财政年份:
    2013
  • 资助金额:
    $ 50.4万
  • 项目类别:
MEASUREMENT OF ETHANOL METABOLISM IN RAT LIVER USING MRS OF [1-13C]PYRUVATE
使用 [1-13C]丙酮酸 MRS 测量大鼠肝脏中的乙醇代谢
  • 批准号:
    8169890
  • 财政年份:
    2010
  • 资助金额:
    $ 50.4万
  • 项目类别:
Metabolic Imaging of the Cardioprotective Effects of Alcohol and ALDH2 Activators
酒精和 ALDH2 激活剂的心脏保护作用的代谢成像
  • 批准号:
    8401178
  • 财政年份:
    2010
  • 资助金额:
    $ 50.4万
  • 项目类别:
Metabolic Imaging of the Cardioprotective Effects of Alcohol and ALDH2 Activators
酒精和 ALDH2 激活剂的心脏保护作用的代谢成像
  • 批准号:
    7765749
  • 财政年份:
    2010
  • 资助金额:
    $ 50.4万
  • 项目类别:
Metabolic Imaging of the Cardioprotective Effects of Alcohol and ALDH2 Activators
酒精和 ALDH2 激活剂的心脏保护作用的代谢成像
  • 批准号:
    8206864
  • 财政年份:
    2010
  • 资助金额:
    $ 50.4万
  • 项目类别:
Metabolic Imaging of the Cardioprotective Effects of Alcohol and ALDH2 Activators
酒精和 ALDH2 激活剂的心脏保护作用的代谢成像
  • 批准号:
    8009887
  • 财政年份:
    2010
  • 资助金额:
    $ 50.4万
  • 项目类别:
MEASUREMENT OF ETHANOL METABOLISM IN RAT LIVER USING MRS OF [1-13C]PYRUVATE
使用 [1-13C]丙酮酸 MRS 测量大鼠肝脏中的乙醇代谢
  • 批准号:
    7955416
  • 财政年份:
    2009
  • 资助金额:
    $ 50.4万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 50.4万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了